{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:16:11Z","timestamp":1792894571259,"version":"4.5.0"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.biopha.2018.09.177","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T12:48:20Z","timestamp":1538830100000},"page":"1415-1424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":264,"special_numbering":"C","title":["The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7692-0925","authenticated-orcid":false,"given":"Ali","family":"Masjedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vida","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0589-5523","authenticated-orcid":false,"given":"Mohammad","family":"Hojjat-Farsangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghasem","family":"Ghalamfarsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5658-2511","authenticated-orcid":false,"given":"Gholamreza","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-882X","authenticated-orcid":false,"given":"Farhad","family":"Jadidi-Niaragh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10074","key":"10.1016\/j.biopha.2018.09.177_bib0005","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.biopha.2018.09.177_bib0010","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2018.09.177_bib0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jconrel.2016.12.012","article-title":"CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice","volume":"246","author":"Jadidi-Niaragh","year":"2017","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.biopha.2018.09.177_bib0020","doi-asserted-by":"crossref","first-page":"8403","DOI":"10.1007\/s13277-015-4732-0","article-title":"Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles","volume":"37","author":"Jadidi-Niaragh","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.biopha.2018.09.177_bib0025","first-page":"1","article-title":"Inhibition of HIF-1\u03b1 enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer, Cancer immunology","author":"Kheshtchin","year":"2016","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.biopha.2018.09.177_bib0030","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/cam4.1013","article-title":"Targeting of crosstalk between tumor and tumor microenvironment by \u03b2\u2010D mannuronic acid (M2000) in murine breast cancer model","volume":"6","author":"Hosseini","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.biopha.2018.09.177_bib0035","doi-asserted-by":"crossref","DOI":"10.1038\/nri.2017.142","article-title":"NF-\u03baB, inflammation, immunity and cancer: coming of age","author":"Taniguchi","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2018.09.177_bib0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ccr.2009.01.009","article-title":"Inflammation and cancer: IL-6 and STAT3 complete the link","volume":"15","author":"Bromberg","year":"2009","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.biopha.2018.09.177_bib0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ccr.2007.12.020","article-title":"Autocrine IL-6 signaling: a key event in tumorigenesis?","volume":"13","author":"Grivennikov","year":"2008","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.biopha.2018.09.177_bib0050","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10549-013-2488-z","article-title":"The role of intratumoral and systemic IL-6 in breast cancer","volume":"138","author":"Dethlefsen","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.biopha.2018.09.177_bib0055","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cam4.174","article-title":"Association between adjuvant regional radiotherapy and cognitive function in breast cancer patients treated with conservation therapy","volume":"3","author":"Shibayama","year":"2014","journal-title":"Cancer Med."},{"issue":"7","key":"10.1016\/j.biopha.2018.09.177_bib0060","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","article-title":"Interleukin-6 signaling pathway in targeted therapy for cancer","volume":"38","author":"Guo","year":"2012","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"10.1016\/j.biopha.2018.09.177_bib0065","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","article-title":"Role of interleukin-6 in cancer progression and therapeutic resistance","volume":"37","author":"Kumari","year":"2016","journal-title":"Tumour Biol."},{"issue":"5","key":"10.1016\/j.biopha.2018.09.177_bib0070","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2174\/1381612822666151124234417","article-title":"Interleukin-6: a critical cytokine in Cancer multidrug resistance","volume":"22","author":"Ghandadi","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2018.09.177_bib0075","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fendo.2017.00293","article-title":"Obesity and breast Cancer: current insights on the role of fatty acids and lipid metabolism in promoting breast Cancer growth and progression","volume":"8","author":"Blucher","year":"2017","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"10.1016\/j.biopha.2018.09.177_bib0080","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bbrc.2011.06.101","article-title":"Cancer-associated adipocytes promotes breast tumor radioresistance","volume":"411","author":"Bochet","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2018.09.177_bib0085","doi-asserted-by":"crossref","first-page":"8859","DOI":"10.1038\/s41598-018-27184-9","article-title":"Interleukin-6\/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells","volume":"8","author":"Gyamfi","year":"2018","journal-title":"Sci. Rep."},{"issue":"34","key":"10.1016\/j.biopha.2018.09.177_bib0090","doi-asserted-by":"crossref","first-page":"57622","DOI":"10.18632\/oncotarget.18038","article-title":"The fat and the bad: mature adipocytes, key actors in tumor progression and resistance","volume":"8","author":"Duong","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.biopha.2018.09.177_bib0095","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"16","key":"10.1016\/j.biopha.2018.09.177_bib0100","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1073\/pnas.82.16.5490","article-title":"Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2)","volume":"82","author":"Hirano","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.biopha.2018.09.177_bib0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4149\/neo_2014_026","article-title":"Coexpression of IL-6 and TNF-alpha: prognostic significance on breast cancer outcome","volume":"61","author":"Tripsianis","year":"2014","journal-title":"Neoplasma"},{"issue":"9","key":"10.1016\/j.biopha.2018.09.177_bib0110","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.7150\/ijbs.4614","article-title":"Interleukin-6--a key regulator of colorectal cancer development","volume":"8","author":"Waldner","year":"2012","journal-title":"Int. J. Biol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2018.09.177_bib0115","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/ijc.27892","article-title":"Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy","volume":"132","author":"Chang","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"1-2","key":"10.1016\/j.biopha.2018.09.177_bib0120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.mce.2011.05.033","article-title":"Interleukin-6: a multifunctional targetable cytokine in human prostate cancer","volume":"360","author":"Culig","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"issue":"12","key":"10.1016\/j.biopha.2018.09.177_bib0125","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00109-013-1080-7","article-title":"The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review","volume":"91","author":"Maccio","year":"2013","journal-title":"J. Mol. Med."},{"issue":"5","key":"10.1016\/j.biopha.2018.09.177_bib0130","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/MPA.0000000000000335","article-title":"Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels","volume":"44","author":"Miura","year":"2015","journal-title":"Pancreas"},{"issue":"1-3","key":"10.1016\/j.biopha.2018.09.177_bib0135","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12026-014-8528-x","article-title":"Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma","volume":"59","author":"Rosean","year":"2014","journal-title":"Immunol. Res."},{"issue":"5","key":"10.1016\/j.biopha.2018.09.177_bib0140","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2018.09.177_bib0145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cytogfr.2008.11.006","article-title":"Cytokine and cytokine receptor gene polymorphisms and their functionality","volume":"20","author":"Smith","year":"2009","journal-title":"Cytokine Growth Factor Rev."},{"issue":"6-7","key":"10.1016\/j.biopha.2018.09.177_bib0150","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejcb.2010.10.007","article-title":"The soluble Interleukin 6 receptor: generation and role in inflammation and cancer","volume":"90","author":"Chalaris","year":"2011","journal-title":"Eur. J. Cell Biol."},{"issue":"3","key":"10.1016\/j.biopha.2018.09.177_bib0155","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cytogfr.2012.04.001","article-title":"Plasticity and cross-talk of interleukin 6-type cytokines","volume":"23","author":"Garbers","year":"2012","journal-title":"Cytokine Growth Factor Rev."},{"issue":"9","key":"10.1016\/j.biopha.2018.09.177_bib0160","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2018.09.177_bib0165","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1432-1327.2001.01867.x","article-title":"Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses","volume":"268","author":"Jostock","year":"2001","journal-title":"Eur. J. Biochem."},{"issue":"2","key":"10.1016\/j.biopha.2018.09.177_bib0170","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cytogfr.2012.09.001","article-title":"Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer","volume":"24","author":"Ataie-Kachoie","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"issue":"Pt 1","key":"10.1016\/j.biopha.2018.09.177_bib0175","first-page":"1","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem. J."},{"issue":"6","key":"10.1016\/j.biopha.2018.09.177_bib0180","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1073\/pnas.90.6.2207","article-title":"Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6","volume":"90","author":"Nakajima","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.biopha.2018.09.177_bib0185","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT pathway for cancer drug discovery","volume":"4","author":"Hennessy","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1-3","key":"10.1016\/j.biopha.2018.09.177_bib0190","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejphar.2010.03.030","article-title":"Naphtho[1,2-b]furan-4,5-dione induces apoptosis of oral squamous cell carcinoma: involvement of EGF receptor\/PI3K\/Akt signaling pathway","volume":"636","author":"Chien","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.09.177_bib0195","first-page":"82","article-title":"Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients","volume":"48","author":"Kozlowski","year":"2003","journal-title":"Rocz. Akad. Med. Bialymst."},{"issue":"6","key":"10.1016\/j.biopha.2018.09.177_bib0200","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1158\/0008-5472.CAN-09-2840","article-title":"Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten","volume":"70","author":"Barbieri","year":"2010","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2018.09.177_bib0205","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/bcr3473","article-title":"A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model","volume":"15","author":"Oh","year":"2013","journal-title":"Breast Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2018.09.177_bib0210","first-page":"2899","article-title":"Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells","volume":"31","author":"Jiang","year":"2011","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.09.177_bib0215","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s13277-015-4477-9","article-title":"The immunobiology of myeloid-derived suppressor cells in cancer","volume":"37","author":"Motallebnezhad","year":"2016","journal-title":"Tumor Biol."},{"issue":"1","key":"10.1016\/j.biopha.2018.09.177_bib0220","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2018.09.177_bib0225","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1002\/ijc.25621","article-title":"IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines","volume":"128","author":"Lederle","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2018.09.177_bib0230","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1186\/bcr1648","article-title":"Oestrogen receptor negative breast cancers exhibit high cytokine content","volume":"9","author":"Chavey","year":"2007","journal-title":"Breast Cancer Res."},{"issue":"3-4","key":"10.1016\/j.biopha.2018.09.177_bib0235","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/sj.bjc.6690394","article-title":"Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma","volume":"80","author":"Fontanini","year":"1999","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2018.09.177_bib0240","first-page":"215","article-title":"Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines","volume":"2","author":"Chiu","year":"1996","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.biopha.2018.09.177_bib0245","doi-asserted-by":"crossref","first-page":"6924","DOI":"10.1158\/0008-5472.CAN-03-2516","article-title":"Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy","volume":"64","author":"Selander","year":"2004","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.09.177_bib0250","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1677\/erc.0.0060139","article-title":"The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2","volume":"6","author":"Singh","year":"1999","journal-title":"Endocr. Relat. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2018.09.177_bib0255","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/bcr425","article-title":"The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer","volume":"4","author":"Purohit","year":"2002","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.09.177_bib0260","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10549-009-0706-5","article-title":"Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25,703 subjects","volume":"122","author":"Yu","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"issue":"7","key":"10.1016\/j.biopha.2018.09.177_bib0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181725","article-title":"IL-6 variant is associated with metastasis in breast cancer patients","volume":"12","author":"Abana","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biopha.2018.09.177_bib0270","first-page":"2935","article-title":"Association of Estrogen Receptor Alpha and Interleukin 6 Polymorphisms with Lymphovascular Invasion, Extranodal Extension, and Lower Disease-Free Survival in Thai Breast Cancer Patients","volume":"17","author":"Sa-Nguanraksa","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.biopha.2018.09.177_bib0275","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1186\/1471-2407-14-759","article-title":"IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort","volume":"14","author":"Markkula","year":"2014","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2018.09.177_bib0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103593","article-title":"The associations between immunity-related genes and breast cancer prognosis in Korean women","volume":"9","author":"Choi","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2018.09.177_bib0285","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial-mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.biopha.2018.09.177_bib0290","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/bjc.2015.29","article-title":"Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells","volume":"112","author":"Ricciardi","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2018.09.177_bib0295","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10549-011-1348-y","article-title":"Beta-Adrenergic receptors (beta-AR) regulate VEGF and IL-6 production by divergent pathways in high beta-AR-expressing breast cancer cell lines","volume":"130","author":"Madden","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.biopha.2018.09.177_bib0300","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.molcel.2012.06.014","article-title":"Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population","volume":"47","author":"Korkaya","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2018.09.177_bib0305","first-page":"177","article-title":"Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies","volume":"3","author":"Tawara","year":"2011","journal-title":"Cancer Manag. Res."},{"issue":"24","key":"10.1016\/j.biopha.2018.09.177_bib0310","doi-asserted-by":"crossref","first-page":"21631","DOI":"10.1074\/jbc.M300609200","article-title":"NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4","volume":"278","author":"Helbig","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2018.09.177_bib0315","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1172\/JCI32533","article-title":"IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland","volume":"117","author":"Sansone","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.biopha.2018.09.177_bib0320","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nrc822","article-title":"Epithelial-mesenchymal transitions in tumour progression","volume":"2","author":"Thiery","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"33","key":"10.1016\/j.biopha.2018.09.177_bib0325","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1038\/onc.2009.180","article-title":"Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells","volume":"28","author":"Sullivan","year":"2009","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.biopha.2018.09.177_bib0330","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1172\/JCI35213","article-title":"Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice","volume":"118","author":"Kujawski","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.biopha.2018.09.177_bib0335","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/bjc.2013.748","article-title":"Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction","volume":"110","author":"Nagasaki","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"21","key":"10.1016\/j.biopha.2018.09.177_bib0340","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1038\/sj.onc.1203551","article-title":"Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors","volume":"19","author":"Hirano","year":"2000","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2018.09.177_bib0345","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2014.05.024","article-title":"Interleukin-6 and its receptors: a highly regulated and dynamic system","volume":"70","author":"Wolf","year":"2014","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.biopha.2018.09.177_bib0350","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1172\/JCI57158","article-title":"Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling","volume":"121","author":"Jones","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.biopha.2018.09.177_bib0355","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.coph.2012.06.008","article-title":"Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease","volume":"12","author":"Kontzias","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2018.09.177_bib0360","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nbt0714-607b","article-title":"Green light for Janssen\u2019s IL-6 blocker","volume":"32","author":"Mullard","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"10.1016\/j.biopha.2018.09.177_bib0365","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1158\/1078-0432.CCR-09-3122","article-title":"Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer","volume":"16","author":"Dorff","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.biopha.2018.09.177_bib0370","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-10-1095","article-title":"Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer","volume":"16","author":"Guo","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2018.09.177_bib0375","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10637-012-9857-z","article-title":"A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer","volume":"31","author":"Hudes","year":"2013","journal-title":"Invest. New Drugs"},{"issue":"5","key":"10.1016\/j.biopha.2018.09.177_bib0380","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2010.08533.x","article-title":"Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma","volume":"152","author":"Hunsucker","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"13","key":"10.1016\/j.biopha.2018.09.177_bib0385","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-12-3349","article-title":"A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease","volume":"19","author":"Kurzrock","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.biopha.2018.09.177_bib0390","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40265-014-0249-x","article-title":"Siltuximab: first global approval","volume":"74","author":"Markham","year":"2014","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.biopha.2018.09.177_bib0395","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/sj.bjc.6605872","article-title":"A phase I\/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer","volume":"103","author":"Rossi","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2018.09.177_bib0400","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/JTO.0000000000000193","article-title":"Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer","volume":"9","author":"Song","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2018.09.177_bib0405","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.12266","article-title":"A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma","volume":"161","author":"Voorhees","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2018.09.177_bib0410","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/978-0-387-69080-3_56","article-title":"Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma","volume":"617","author":"Cavarretta","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2018.09.177_bib0415","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.clml.2012.12.010","article-title":"Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma","volume":"13","author":"Chari","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.biopha.2018.09.177_bib0420","first-page":"13","article-title":"Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-alpha-positive breast cancer","volume":"8","author":"Casneuf","year":"2016","journal-title":"Breast Cancer Dove Med. Press (Dove Med Press)"},{"issue":"2","key":"10.1016\/j.biopha.2018.09.177_bib0425","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2018.09.177_bib0430","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1365-2125.2011.03964.x","article-title":"Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study","volume":"72","author":"Xu","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2018.09.177_bib0435","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.V78.5.1198.1198","article-title":"Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia","volume":"78","author":"Klein","year":"1991","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.biopha.2018.09.177_bib0440","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1158\/1078-0432.CCR-09-1483","article-title":"A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma","volume":"15","author":"Fulciniti","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.biopha.2018.09.177_bib0445","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/annrheumdis-2011-200704","article-title":"A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate","volume":"71","author":"Mease","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.biopha.2018.09.177_bib0450","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","article-title":"A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer","volume":"11","author":"Bayliss","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2018.09.177_bib0455","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/nbt1166","article-title":"Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains","volume":"23","author":"Silverman","year":"2005","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"10.1016\/j.biopha.2018.09.177_bib0460","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.ejca.2012.11.038","article-title":"Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression","volume":"49","author":"Oguro","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2018.09.177_bib0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102436","article-title":"Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer","volume":"9","author":"Ando","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2018.09.177_bib0470","article-title":"IL6 blockade potentiates the anti-tumor effects of gamma-secretase inhibitors in Notch3-expressing breast cancer","author":"Wang","year":"2017","journal-title":"Cell Death Differ."},{"issue":"6","key":"10.1016\/j.biopha.2018.09.177_bib0475","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2012.44.2020","article-title":"Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia","volume":"31","author":"Ando","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2018.09.177_bib0480","doi-asserted-by":"crossref","first-page":"812","DOI":"10.4049\/jimmunol.1103797","article-title":"The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice","volume":"190","author":"Narita","year":"2013","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2018.09.177_bib0485","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1517\/14728222.2013.830105","article-title":"gp130: a promising drug target for cancer therapy","volume":"17","author":"Xu","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"issue":"12","key":"10.1016\/j.biopha.2018.09.177_bib0490","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrrheum.2014.127","article-title":"IL-6 biology: implications for clinical targeting in rheumatic disease","volume":"10","author":"Calabrese","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"issue":"5","key":"10.1016\/j.biopha.2018.09.177_bib0495","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ijc.29445","article-title":"Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer","volume":"137","author":"Goumas","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2018.09.177_bib0500","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/0008-5472.CAN-06-3641","article-title":"Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor","volume":"67","author":"Yoshio-Hoshino","year":"2007","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.biopha.2018.09.177_bib0505","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1002\/j.1460-2075.1994.tb06931.x","article-title":"Rational design of a receptor super-antagonist of human interleukin-6","volume":"13","author":"Savino","year":"1994","journal-title":"EMBO J."},{"issue":"5","key":"10.1016\/j.biopha.2018.09.177_bib0510","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ijc.1388","article-title":"The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells","volume":"93","author":"Honemann","year":"2001","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2018.09.177_bib0515","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1124\/jpet.102.036137","article-title":"Biological activity of a novel nonpeptide antagonist to the interleukin-6 receptor 20S,21-epoxy-resibufogenin-3-formate","volume":"303","author":"Hayashi","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2018.09.177_bib0520","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.bbrc.2004.08.196","article-title":"Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist","volume":"323","author":"Enomoto","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"25","key":"10.1016\/j.biopha.2018.09.177_bib0525","doi-asserted-by":"crossref","first-page":"14764","DOI":"10.1074\/jbc.271.25.14764","article-title":"Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein","volume":"271","author":"Chevalier","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"17","key":"10.1016\/j.biopha.2018.09.177_bib0530","doi-asserted-by":"crossref","first-page":"13743","DOI":"10.1074\/jbc.M112.349167","article-title":"Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling","volume":"287","author":"Sommer","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"23","key":"10.1016\/j.biopha.2018.09.177_bib0535","doi-asserted-by":"crossref","first-page":"14728","DOI":"10.1073\/pnas.232562799","article-title":"Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130","volume":"99","author":"Hayashi","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"32","key":"10.1016\/j.biopha.2018.09.177_bib0540","doi-asserted-by":"crossref","first-page":"10822","DOI":"10.1021\/bi050439+","article-title":"Binding of madindoline A to the extracellular domain of gp130","volume":"44","author":"Saleh","year":"2005","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.biopha.2018.09.177_bib0545","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1158\/1535-7163.MCT-12-1082","article-title":"Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer","volume":"12","author":"Xu","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.biopha.2018.09.177_bib0550","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2018.09.177_bib0555","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1021\/jm401144z","article-title":"Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6\/GP130 interface","volume":"57","author":"Li","year":"2014","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2018.09.177_bib0560","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1210\/en.2012-2038","article-title":"Inhibitory effects of a bazedoxifene\/conjugated equine estrogen combination on human breast cancer cells in vitro","volume":"154","author":"Song","year":"2013","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.biopha.2018.09.177_bib0565","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4049\/jimmunol.1402908","article-title":"A novel small-molecule inhibitor targeting the IL-6 receptor beta subunit, glycoprotein 130","volume":"195","author":"Hong","year":"2015","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2018.09.177_bib0570","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/JTO.0b013e31820d9d11","article-title":"Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models","volume":"6","author":"Sun","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2018.09.177_bib0575","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1535-7163.MCT-11-0951","article-title":"Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer","volume":"11","author":"Seavey","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.biopha.2018.09.177_bib0580","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095993","article-title":"Inhibition of the JAK2\/STAT3 pathway reduces gastric cancer growth in vitro and in vivo","volume":"9","author":"Judd","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.biopha.2018.09.177_bib0585","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1158\/1535-7163.MCT-09-0947","article-title":"Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3","volume":"9","author":"Yang","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2018.09.177_bib0590","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1756-9966-29-51","article-title":"Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro","volume":"29","author":"Huang","year":"2010","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.09.177_bib0595","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3390\/cancers6020926","article-title":"Transcription factor STAT3 as a novel molecular target for Cancer prevention","volume":"6","author":"Xiong","year":"2014","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2018.09.177_bib0600","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2015.09.039","article-title":"AG490, a Jak2 inhibitor, suppressed the progression of murine ovarian cancer","volume":"766","author":"Kobayashi","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2018.09.177_bib0605","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.clml.2014.08.003","article-title":"A phase I\/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia","volume":"15","author":"Pemmaraju","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"12","key":"10.1016\/j.biopha.2018.09.177_bib0610","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1158\/1535-7163.MCT-10-0550","article-title":"Inhibition of constitutive activation of STAT3 by curcurbitacin-I (JSI-124) sensitized human B-leukemia cells to apoptosis","volume":"9","author":"Ishdorj","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.biopha.2018.09.177_bib0615","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2006.09.018","article-title":"Stattic: a small-molecule inhibitor of STAT3 activation and dimerization","volume":"13","author":"Schust","year":"2006","journal-title":"Chem. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2018.09.177_bib0620","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128406","article-title":"Eriocalyxin B inhibits STAT3 signaling by covalently targeting STAT3 and blocking phosphorylation and activation of STAT3","volume":"10","author":"Yu","year":"2015","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.biopha.2018.09.177_bib0625","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1016\/j.bmcl.2010.09.117","article-title":"A novel small-molecule inhibitor of IL-6 signalling","volume":"20","author":"Zinzalla","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"18","key":"10.1016\/j.biopha.2018.09.177_bib0630","doi-asserted-by":"crossref","first-page":"6603","DOI":"10.1158\/0008-5472.CAN-03-4041","article-title":"G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis","volume":"64","author":"Jing","year":"2004","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2018.09.177_bib0635","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/13543780802565791","article-title":"Targeting STAT3 in cancer: how successful are we?","volume":"18","author":"Yue","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2018.09.177_bib0640","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1471-2407-7-111","article-title":"Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells","volume":"7","author":"Chen","year":"2007","journal-title":"BMC Cancer"},{"issue":"13","key":"10.1016\/j.biopha.2018.09.177_bib0645","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1073\/pnas.0409894102","article-title":"A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells","volume":"102","author":"Song","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.biopha.2018.09.177_bib0650","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s13277-013-0832-x","article-title":"Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions","volume":"34","author":"Jadidi-Niaragh","year":"2013","journal-title":"Tumor Biol."},{"issue":"10","key":"10.1016\/j.biopha.2018.09.177_bib0655","doi-asserted-by":"crossref","first-page":"7339","DOI":"10.1007\/s13277-015-4004-z","article-title":"Myeloid-derived suppressor cells in B cell malignancies","volume":"36","author":"Yazdani","year":"2015","journal-title":"Tumor Biol."},{"issue":"6","key":"10.1016\/j.biopha.2018.09.177_bib0660","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/onc.2015.132","article-title":"Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies","volume":"35","author":"Raggi","year":"2016","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.biopha.2018.09.177_bib0665","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s13277-013-0743-x","article-title":"The role of natural killer T cells in B cell malignancies","volume":"34","author":"Ghalamfarsa","year":"2013","journal-title":"Tumor Biol."},{"issue":"3","key":"10.1016\/j.biopha.2018.09.177_bib0670","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/jcp.25873","article-title":"Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer","volume":"233","author":"Kazemi","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"3","key":"10.1016\/j.biopha.2018.09.177_bib0675","first-page":"769","article-title":"Immunotherapeutic approaches for cancer therapy: an updated review, Artificial Cells","volume":"44","author":"Kazemi","year":"2016","journal-title":"Nanomed. Biotechnol."},{"issue":"8","key":"10.1016\/j.biopha.2018.09.177_bib0680","doi-asserted-by":"crossref","first-page":"10021","DOI":"10.1007\/s13277-016-5059-1","article-title":"Mechanisms of tumor cell resistance to the current targeted-therapy agents","volume":"37","author":"Khamisipour","year":"2016","journal-title":"Tumor Biol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333221835114X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333221835114X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T06:40:40Z","timestamp":1777272040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333221835114X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":136,"alternative-id":["S075333221835114X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.09.177","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.09.177","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}